Pursuant to Regulation 30 Read with Schedule III of the SEBI(Listing Obligations and Disclosure Requirnments ) Regulations 2015, we hereby inform you about the change in Senior Manaaement ....

Ref. No.: JPL/CS/2342/2026 Date: 04th September, 2026. BSE Ltd., P J Towers, Dalal Street, Mumbai - 400 001. Script Code :524731 Sub.: Intimation of Change in Senior Management Personnel of the Company. Ref.: Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Dear Sir, Pursuant to Regulation 30 read with Para A (7) of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform that the Board of Directors of the Company, by way of resolution passed by circulation on 04th September 2026, has approved the elevation of Shri. Prem Ashish Bhuta- from “Management Associate” to “Associate Vice President (AVP) – Strategic Initiatives” (Senior Management Personnel) of the Company with effect from 04th September, 2026, upon recommendation of the Nomination and Remuneration Committee and prior approval of the Audit Committee of the Company. Shri. Prem Ashish Bhuta is related to Shri. Ashish U. Bhuta, the Promoter and Chairman & Managing Director of the Company. The details required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. HO/49/14/14(7)2025-CFDPOD2/I/3762/2026 dated 30th January, 2026, is enclosed as Annexure - A. The aforementioned information is also available on the website of the Company viz. www.Jenburkt.com. Kindly acknowledge. Yours faithfully, For Jenburkt Pharmaceuticals Limited, Ashish R. Shah Sr. VP and Company Secretary and Compliance Officer Encl.: As stated above. Annexure -A Sr. Particulars Details 1. Name Shri. Prem Ashish Bhuta 2. Reason for change viz. Shri Prem Ashish Bhuta, an existing employee of the Company, is appointment, re- elevated from “Management Associate” to “Associate Vice appointment, President (AVP) – Strategic Initiatives” with effect from 04th resignation, removal, September, 2026. He will be categorized as Senior Managerial death or otherwise; Personnel of the Company. 3. date of Elevated with effect from 04th September, 2026. appointment/re- appointment/cessation In employment since 13th July, 2021 (as applicable) & term of appointment/re- appointment; 4. brief profile (in case of Qualification: appointment); Shri Prem Ashish Bhuta, aged 26 years, holds a degree of “Master of Science in Integrated Marketing” (with distinction) from New York University, School of Professional Studies, New York-USA, and a Bachelor of Commerce (Honours) from Narsee Monjee Institute of Management Studies, Mumbai. Experience: Shri Prem Ashish Bhuta brings over 5 years of cross-functional experience across finance, sales and marketing operations, consumer research, business analytics and technology-led initiatives within the pharmaceutical sector. Associated with Jenburkt Pharmaceuticals Limited since 13th July, 2021, he has progressed through roles including Management Trainee, Officer – Finance and Management Associate. His experience spans marketing and market research, new product development, e-commerce, sales tracking and analytics, inventory and logistics management, and exposure to pharmaceutical manufacturing processes. He was part of the core team responsible for building ZIXA Strong, OTC topical pain relief brand under Jenburkt Wellness division, and has also contributed to the Company’s broader technology modernisation efforts. These initiatives have included the deployment of artwork management software, an upgrade to the Company’s Laboratory Information Management System (LIMS), and the rollout of a real-time sales tracking application now in active use by a field force of over 700 employees. During his academic tenure in the United States, he undertook strategic and consumer research projects in collaboration with organisations including Samsung Electronics America and Coca- Cola Southwest Beverages, gaining experience in customer segmentation, data analysis, feasibility assessment and strategic recommendations. His combination of cross-functional operating experience, analytical capability and exposure to business transformation initiatives positions him well to contribute as ‘Associate Vice President – Strategic Initiatives’, with a focus on identifying, evaluating and driving initiatives across functions. 5. disclosure of NA relationships between directors (in case of appointment of a director).